Autoimmune thyroiditis following interleukin-2 and LAK cell therapy for metastatic renal cell carcinoma: Correlation with tumor regression

C. Besana, M. G. Sabbadini, C. Corti, G. Di Lucca, M. Foppoli, M. Marcatti, S. Heltai, C. Rugarli

Research output: Contribution to journalArticle

Abstract

A 63-year-old woman receiving recombinant interleukin-2 (rIl-2) + lymphokine activated killer cells for metastatic renal cell carcinoma developed autoimmune thyroiditis with clinical thyroidism and high titer anti-thyroglobulin and anti-microsomal antibodies. The onset of thyroid dysfunction was associated with tumor regression and resulted in complete response at the end of the treatment. Cytologic and cytofluorimetric studies on thyroid tissue showed two distinct populations, mainly consisting of small llymphocytes and large thyrocytes, and the latter expressed MHC class II antigens. After completion of rIL-2 treatment, hypothyroidism gradually decreased until resolution; complete tumor remission lasted 18 months. Mechanisms underlying the association between autoimmune thyroiditiss and cancer regression are discussed.

Original languageEnglish
Pages (from-to)339-341
Number of pages3
JournalTumori
Volume77
Issue number4
Publication statusPublished - 1991

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research

Cite this

Besana, C., Sabbadini, M. G., Corti, C., Di Lucca, G., Foppoli, M., Marcatti, M., Heltai, S., & Rugarli, C. (1991). Autoimmune thyroiditis following interleukin-2 and LAK cell therapy for metastatic renal cell carcinoma: Correlation with tumor regression. Tumori, 77(4), 339-341.